An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

Pharmaceutical giant Novo Nordisk says an oral version of semaglutide — the active ingredient in blockbuster drugs Ozempic ...

Two major clinical trials evaluating the potential of the weight-loss drug semaglutide to treat Alzheimer’s disease have ...

Novo Nordisk's blockbuster weight loss drug semaglutide failed to slow Alzheimer's progression in trials. The studies had ...

Despite encouraging biomarker shifts, oral semaglutide failed to slow cognitive decline in early Alzheimer’s, leading to an early end of the trial extension.

A massive real-world study comparing tirzepatide and semaglutide reveals both drugs deliver strong, early cardiovascular ...

Novo Nordisk shares plunge after its oral semaglutide Alzheimer’s trials fail, raising fresh doubts over its push into a ...

Based on the efficacy results, Novo Nordisk has made the decision to discontinue the 1-year extension periods for these trials.

Both semaglutide and tirzepatide are associated with improvements in quality of life for adults with obesity, though ...

A Novo Nordisk challenge has driven Regen Doctors to voluntarily discontinue compounded semaglutide product claims, adding to ...

But perhaps the larger story associated with the unsurprising result is the market reaction, as Novo's shares fell by nearly 9% at the U.S. market open Monday.

Novo Nordisk's Alzheimer's trials using semaglutide failed to show progress in slowing the disease, affecting the company's shares and future market opportunities. Despite high hopes, the two-year ...